• OmniAb’s third-quarter 2026 net loss narrowed year over year to $15.73 million.
• Revenue climbed 78% to $3.99 million, driven primarily by higher service and xPloration revenue.
• A new Eli Lilly ion channel collaboration includes eligibility for up to $370 million in milestone payments and tiered royalties.
• Full-year 2026 revenue guidance rose to $35 million–$39 million from $32 million–$36 million previously.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OmniAb Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610300740BIZWIRE_USPR_____20261030_BW075655) on October 30, 2026, and is solely responsible for the information contained therein.